187 related articles for article (PubMed ID: 2287079)
1. [Low dose continuous infusion therapy with etoposide (VP-16) and cytosine arabinoside (Ara-C) for a patient with refractory acute myelogenous leukemia].
Koyama S; Itou S; Shibata A
Rinsho Ketsueki; 1990 Nov; 31(11):1891-2. PubMed ID: 2287079
[TBL] [Abstract][Full Text] [Related]
2. [Refractory acute myelogenous leukemia successfully treated with a continuous infusion chemotherapy of low dose aclarubicin and cytosine arabinoside: a case report].
Kawada H; Komatsuda M; Masumoto A; Fukuda R; Watanabe S; Yonekura S; Ichikawa Y; Nagao T; Arimori S
Rinsho Ketsueki; 1993 May; 34(5):667-9. PubMed ID: 8315839
[TBL] [Abstract][Full Text] [Related]
3. [Continuous infusion therapy with low dose cytosine arabinoside and etoposide in acute myelogenous leukemia patients hardly tolerable for intensive combination chemotherapy].
Tsurumi H; Miura T; Yamada T; Sawada M; Nakamura N; Tomoda T; Takahashi T; Oyama M; Moriwaki H; Muto Y
Rinsho Ketsueki; 1995 Jul; 36(7):657-64. PubMed ID: 7563593
[TBL] [Abstract][Full Text] [Related]
4. [Low-dose oral etoposide and subcutaneous injection of low-dose cytosine arabinoside (Et-A non i.v.) with or without minimum anthracycline for refractory acute non-lymphoblastic leukemia].
Tsukaguchi M; Furukawa Y; Kitani T
Gan To Kagaku Ryoho; 1998 Aug; 25(10):1603-7. PubMed ID: 9725056
[TBL] [Abstract][Full Text] [Related]
5. [Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)].
Tsukaguchi M; Furukawa Y; Shibano M; Kitani T
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1119-23. PubMed ID: 15272598
[TBL] [Abstract][Full Text] [Related]
6. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
7. Continuous infusion intermediate-dose cytarabine, mitoxantrone, plus etoposide for refractory or early relapsed acute myelogenous leukemia.
Lee JH; Choi SJ; Lee JH; Lee YS; Seol M; Ryu SG; Jang S; Park CJ; Chi HS; Lee JS; Kim WK; Lee KH
Leuk Res; 2006 Feb; 30(2):204-10. PubMed ID: 16055185
[TBL] [Abstract][Full Text] [Related]
8. Continuous drip infusion of low dose cytarabine and etoposide with granulocyte colony-stimulating factor for elderly patients with acute myeloid leukaemia ineligible for intensive chemotherapy.
Kanemura N; Tsurumi H; Kasahara S; Hara T; Yamada T; Sawada M; Goto N; Kitagawa J; Shimizu M; Oyama M; Moriwaki H
Hematol Oncol; 2008 Mar; 26(1):33-8. PubMed ID: 17918772
[TBL] [Abstract][Full Text] [Related]
9. [Successful treatment with G-CSF and continuous infusion of low-dose cytarabine and etoposide for therapy-related acute myeloid leukemia developed during chemotherapy for malignant lymphoma].
Yamamoto K; Nagata K; Morita Y; Hamaguchi H
Rinsho Ketsueki; 2002 Jun; 43(6):488-92. PubMed ID: 12134707
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy with mitoxantrone and etoposide in refractory acute myelogenous leukemia.
Ho AD; Lipp T; Ehninger G; Meyer P; Freund M; Hunstein W
Cancer Treat Rep; 1986 Aug; 70(8):1025-7. PubMed ID: 3460698
[TBL] [Abstract][Full Text] [Related]
11. [Etoposide (VP 16/NK 171) and cytosine arabinoside combination chemotherapy in refractory childhood leukemia].
Esumi N; Todo S; Arakawa S; Imashuku S
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):951-8. PubMed ID: 3963859
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
[TBL] [Abstract][Full Text] [Related]
13. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
[TBL] [Abstract][Full Text] [Related]
14. [High dose ara-C therapy induced bradycardia in an acute myeloid leukemia patient with inv (16)(p13q22)].
Kumagawa M; Suzuki K; Nagano M; Takamatsu Y; Suzumiya J; Tamura K
Rinsho Ketsueki; 2003 Jun; 44(6):404-6. PubMed ID: 12884821
[TBL] [Abstract][Full Text] [Related]
15. [An elderly patient with myelodysplastic syndrome successfully treated with combination of granulocyte-colony stimulating factor and continuous-drip infusion of low-dose cytarabine and etoposide].
Yamada T; Tsurumi H; Hara T; Fukuno K; Goto H; Oyama M; Moriwaki H
Rinsho Ketsueki; 2000 Mar; 41(3):218-21. PubMed ID: 10774251
[TBL] [Abstract][Full Text] [Related]
16. [Long-term oral administration of etoposide (VP-16) for the patients with refractory or relapsed acute non-lymphocytic leukemia].
Koyama S; Saitou H; Kashiwaba M
Rinsho Ketsueki; 1991 Jul; 32(7):736-42. PubMed ID: 1920837
[TBL] [Abstract][Full Text] [Related]
17. [A case of complete remission from acute myelogenous leukemia in second relapse achieved using an intermediate-dose cytosine arabinoside (ID Ara-C) regimen].
Yoshida M; Owada N; Sasaki R; Sakamoto S; Miura Y
Gan To Kagaku Ryoho; 1986 Jan; 13(1):143-6. PubMed ID: 3455805
[TBL] [Abstract][Full Text] [Related]
18. [Myelogenous leukemia in children. ANLL9205 study by Children's Cancer and Leukemia Study Group (CCLSG)].
Mimaya J; Horikoshi Y; Shimizu H; Maeda H; Koizumi S; Kawakami K; Watanabe A; Utsumi J; Kikuta A; Oka T; Mugishima H; Kawamura N; Gushiken T; Ohta S; Yamamura Y; Ishida Y; Sekine I; Okada N; Fujimoto T
Rinsho Ketsueki; 1997 Feb; 38(2):100-7. PubMed ID: 9059063
[TBL] [Abstract][Full Text] [Related]
19. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
[TBL] [Abstract][Full Text] [Related]
20. A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage. A pilot study.
Kuriya S; Murai K; Miyairi Y; Utsugisawa T; Narigasawa Y; Ito T; Shimosegawa K; Ishida Y
Cancer; 1996 Aug; 78(3):422-6. PubMed ID: 8697386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
